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Abstract
Background: Melanoma is the most serious type of skin cancer that can lead to metastasis. The
main treatment for melanoma is surgical removal — a wide excision. Patients with advanced
melanoma require further treatment such as chemotherapy or immunotherapy due to the concern
of continuous spread.
Purpose: Literature review of studies to examine if patients with advanced melanoma, treated
with immunotherapy, enjoy better overall survival rates than patients treated with chemotherapy?
Methods: A comprehensive literature review was conducted using <Pub Med> using the search
terms <(advanced melanoma) AND (immunotherapy)) AND (chemotherapy)) AND (skin
cancer)>. Inclusion criteria were studies that were related to immunotherapy and chemotherapy
among advanced melanoma patients. Exclusion criteria were studies that were completed more
than five years ago, free text was available, other languages besides English, non-human species,
and any patient under the age of 18 years old.
Conclusions: Immunotherapy is a more sustainable option for treating patients with advanced
melanoma. It has been proven that immunotherapy offers patients better outcomes versus treating
advanced melanoma with chemotherapy.
Key Words: “advanced melanoma”, “immunotherapy”, “chemotherapy”, “skin cancer”
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Introduction
Among skin cancers, melanoma represents the most aggressive type and is responsible
for the majority of deaths among skin cancer patients. Melanoma is especially fearsome as it
often spreads to other parts of the body. According to the American Academy of Dermatology
(AAD), more than 197,000 Americans will be diagnosed with advanced melanoma in 2022,
affecting slightly more women than men, yet more men will die from melanoma.1 When detected
early, and before it spreads to lymph nodes, melanoma has a ninety-nine percent five-year
survival rate.1 However, that figure falls to sixty-eight percent if melanoma spreads to nearby
lymph nodes, and then plummets to thirty percent once it spreads to distant lymph nodes and
other organs.1 The AAD estimates nearly twenty Americans die each day from
melanoma-related complications. 1
Melanoma may show itself on the skin in many ways: as a mole that changes shape or
color, a spot that may resemble a mole or freckle or age spot but appears slightly different, spots
with jagged borders and changing colors, or a dome-shaped growth that is firm to the touch and
looks like a sore that may bleed. 1 Melanoma may also appear as a dark-brown or black vertical
line beneath a fingernail or toenail, or a band of darker skin around a fingernail or toenail. 1
Examining the efficacy of melanoma treatments is important as the incidence of
melanoma, according to the American Cancer Society (ACS), has been increasing in recent
decades. 2 This alarming fact is due to the use of artificial sun lamps and prolonged exposure to
ultraviolet light. And despite pleading from health officials and their own physicians and
healthcare providers, people continue to engage in unsafe behaviors exposing their skin to
potentially damaging ultra violet (UV) radiation. 2 Of course, climate change contributes to these
unsafe practices, with summers becoming increasingly hotter; just this summer heat records are
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being shattered across the globe, and millions of people are seeking relief outdoors, millions of
people often unaccustomed to such sun exposure.
So, new beachgoers, and even those who traditionally worship the sun, must be aware
that even one blistering sunburn as a child, or five or more between the ages of fifteen and
twenty, increases melanoma risk by up to eighty percent. The message, often repeated, is this:
“Unprotected exposure to the sun’s UV rays remains the most preventable risk factor for skin
cancer.”2
Despite healthcare professionals’ pleading with everyone to apply sunscreen, incidents of
melanoma march on. But, early detection can prevent complications. This means performing
self-exams to check the skin for signs (as above) of melanoma, and then seeing a physician for a
definitive diagnosis. Unfortunately, the messages, the self-exams, the use of sunscreens are either
forgotten or ignored, leading to diagnoses of stage III and state IV melanoma.
When melanoma is classified as stage III, this means it has spread to one or more lymph
glands and nearby skin.1 And by stage IV, the most advanced stage, it means melanoma has
spread to one or multiple parts of the body including non-adjacent skin or lymph nodes, and to
internal organs including the lungs or brain.1 Thus, when a patient is diagnosed with stage III or
stage IV melanoma, they and their physician face a choice: which treatment will offer greatest
chance of survival with minimal side effects, traditional chemotherapy, or any of the newer
immunotherapies or, perhaps a combination of both? Thisliterature review will examine
treatment therapies for advanced melanoma to determine if patients will have greater survival
rates with immunotherapy, chemotherapy, or a therapy protocol combining the two. Further, a
comprehensive discussion will lead to conclusions, including next steps, as well as potential for
future research.
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Methods
A comprehensive literature review was conducted using <Pub Med> using the search
terms <(advanced melanoma) AND (immunotherapy)) AND (chemotherapy)) AND (skin
cancer)>. Inclusion criteria were studies that were related to immunotherapy and chemotherapy
among advanced melanoma patients. Exclusion criteria were studies that were completed more
than five years ago, free text was available, other languages besides English, non-human species,
and any patient under the age of eighteen-years-old.
The abstract includes sources relevant because the death rate associated with melanoma is
increasing annually and there is generally a lack of awareness among people about melanoma
risk factors. Sources were obtained through Pub Med, and then they were analyzed, with special
attention paid to survival rates. From this analysis, a recognizable trend emerged in terms of
which treatment may be most effective.
Further, studies were limited to those conducted within the previous five years to ensure
the most accurate and current data to propose effective treatment for patients with advanced
melanoma. The age limit — only patients eighteen years of age and older — was selected as
adults report far greater incidence of melanoma than children. And, only English-language
studies were reviewed to allow for a complete understanding of the data. Treatment options for
advanced melanoma are becoming more advanced, so a comparison of these options is useful
and may lead to future studies.
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Pub Med
((advanced melanoma) AND
(chemotherapy) AND
(immunotherapy) AND (skin
cancer))
n=804

Exclude articles outside of the last
five years and free text available
n=214

Exclude any other languages aside
from English and non- human
species
n=185

Exclude participants under 18 years
old
n=95

Inclusion of participants with advanced
melanoma (Stage III and IV).
n=35

Literature Review
In a study published in 2019 by Larkin et al patients were randomly assigned in a 1:1:1
ratio to receive a different combination of immunotherapy – nivolumab plus ipilimumab,
nivolumab, and ipilimumab.3 This study included adult patients with confirmed stage III or stage
IV advanced melanoma.3 Participants were selected between July 2013 through March 2014
where a total of 1296 patients were enrolled, but only 945 underwent randomization.3 The
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patients were followed-up at a minimum of sixty months. This study revealed that the overall
survival was longer in patients who were treated with nivolumab- containing groups than in the
ipilimumab group.3 This study also incorporated the quality of life among patients that receive
melanoma therapy.3 The EQ-5D-3L results from this five-year analysis did not show significant
deterioration in health-related quality of life among the nivolumab groups but did acknowledge
that there was meaningful deterioration that was observed among the patients that used
ipilimumab.3 Overall, patients with advanced melanoma in this study had a greater long-term
survival at five years and quality of life by using the nivolumab plus ipilimumab or nivolumab
alone than those who received ipilimumab.3
Similarly, a study published two years later by Najjar et al, enrolled thirty-one patients
(only thirty were evaluated) and examined neoadjuvant pembrolizumab, an immunotherapy drug,
and high dose IFNα-2b therapy in patients with reseceptable advanced melanoma.4 Yet, Larkin
and Chiarion-Sileni found that the specific use of nivolumab immunotherapy allowed for a better
quality of life in their 2019 study that followed sixty-eight patients for five years.3 Overall, the
patient would undergo about one year of treatment including a definitive surgery to remove the
melanoma.4 High dose IFNα-2b and pembrolizumab were discontinued in seventy-three and
43% of the patients that were enrolled in the trial.4 The immunotherapy drug and HDI
medication that were used concurrently demonstrated promising clinical activity regardless of
the high rates of discontinuation.4 Although there are different types of immunotherapy, they do
not all act similarly. Indeed, many patients in this study discontinued their therapy but still were
left with promising results.
Tarhini et al found that neoadjuvant therapy was classified as fairly safe and portrayed a
significant impact on T-cell fraction.5 This study examined both male and female adult patients
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diagnosed with advanced melanoma.5 This study used neoadjuvant immunotherapy – ipilimumab
because it has capabilities to revamp the overall standard of care for advanced melanoma.5 The
safety and efficacy of the therapy were both evaluated while also examining T-cell fractions in
the heme and tumor. 5 However, only twenty-eight patients were evaluated, and of those eleven
relapsed and five died.5
One other study by Kleef at al examined reported deaths. This research study is a
retrospective that examines both the safety and efficacy of a new therapy in more than 100 stage
IV cancer patients with various types of cancer who have reached the end point in terms of
available conventional therapies.6 Although immunotherapy has made significant improvement
in the overall survival of patients with advanced melanoma, at times it comes with a cost of
adverse events — moderately elevated serum glutamic oxaloacetic transaminase (GOT) and
serum glutamic pyruvic transaminase (GPT), , diarrhea, skin rash — that later occur.6 These
adverse events lead to patients having to discontinue the immunotherapy. In this study, fifty-nine
percent of patients had suffered from some type of adverse event leading to a discontinuation of
therapy in 24.5% of patients and one death.6 As mentioned from Larkin et al, an immunotherapy
combination of ipilimumab and nivolumab treatment has achieved a three-year survival rate of
sixty-three percent for patients with advanced melanoma.3
The efficacy of immunotherapy as an effective treatment for melanoma, which included
less frequent hospitalization, was further demonstrated in a study.7 This is a cohort study that
evaluates hospitalization rates in patients with advanced melanoma receiving either
pembrolizumab therapy or ipilimumab plus nivolumab therapy.7 Both of these therapies are
approved by the Food and Drug Administration in patients who acquire advanced melanoma.
The duration of the study was twelve months.7 The patients selected were from various U.S.
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academic centers. This study is important in that it examines patients with advanced melanoma
who underwent chemotherapy and had a particularly low survival rate and high toxicity.7 The
patient population was greater than or equal to eighteen-years-old.7 This study concluded that
patients on the pembrolizumab therapy had a much lower chance of being admitted into the
hospital as compared to patients receiving the dual therapy, ipilimumab plus nivolumab.7 The
results support the pembrolizumab as it is proven to decrease hospitalizations as compared to the
dual therapy or chemotherapy alone.7
Further, a retrospective study focuses on patients with advanced melanoma taking the
nivolumab therapy beyond progression.8 The individuals in this study were treated with
nivolumab after first degree progression.8 The goal of the study was to examine possible
benefits, as well as efficacy and safety, of nivolumab therapy. Long et al concluded that the
majority of selected patients treated with this therapy had clinical benefits and tolerated the
drug.8
Likewise, Yamazaki et al conducted a study where patients were also being treated with
Nivolumab. This study examines postmarketing data of the antibody nivolumab in patients of
Japanese descent who have acquired advanced melanoma.9 The type of melanoma in this specific
population was so advanced in nature that it was unresectable.9 In the study, the patients were to
take nivolumab at various dosages for a duration of every two to three weeks.9 The goal was to
evaluate the responsive and survival rate at this particular population. The results indicated that
in the 124 patients observed, the most common melanoma type was mucosal melanoma.9 The
average survival duration was roughly fifteen months.9 This study concluded that those using
nivolumab had lower survival rates and the efficacy of nivolumab therapy does not show highly
promising results in clinical practice.9
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Skudaslski et al provides more information about systemic therapies for patients with
melanoma. While melanoma deaths continue to be on the rise, systemic therapies are often
approached first due to the difficulty of surgical clearance. Chemotherapy was the gold
standard.10 Yet, that changed after 2011 because of the lack of positive response and survival
rates. Since that time, various systemic therapies have come into play, some even being approved
by the FDA, including nivolumab.10 Therapies such as nivolumab have been shown to have
favorable results in treating advanced melanoma.10 Thus, practitioners such as dermatological
oncologists should implement newer therapies such as these in hopes for favorable results for
their patients. While more testing and research must be completed, it is more evident that these
therapies have shown much favorable results as compared to chemotherapy.
Finally, the case report published by Gorayski et al reviewing treatment on a 71-year-old
male showed how immunotherapy compares to other treatments and discusses the eradication of
micro-metastases wherever it is in the body.11 The patient ignored fungating and bleeding
malignant melanoma. Surgical options were considered, but due to severe complications and
significant morbidity, a conjoined decision was made against surgical intervention.11 The
untreated melanoma led to the patient adapting a condition where he lacked healthy red blood
cells which normally would carry enough oxygen to your body’s tissues as well as debilitated
cardiac issues including heart failure.11 This patient was treated with combined radiotherapy and
immunotherapy for four weeks.11 The combination therapy resulted in a response, but after the
fifth round of immunotherapy the patient developed colitis and the immunotherapy was
discontinued.11 Immunotherapy has made significant improvements in total survival within the
last decade and has increased the survival to more than three years compared to a six-month
survival with chemotherapy.
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Immunotherapy and Chemotherapy
Jenkins et al evaluates various treatments for advanced melanoma in 2020 and beyond. In
recent years, new therapies have been introduced to significantly benefit patients with advanced
melanoma. These therapies have shifted from chemotherapy, traditionally the gold standard of
care.12 Though there is progress in advanced melanoma, other therapeutic approaches are
available that are required for patients that do not respond to current therapies. Because of the
target of molecular therapies, there has been an outstanding improvement in the overall survival
in people suffering from advanced melanoma. As time progresses, this study and others
emphasize the importance of seeking advancements that can overcome resistance with current
therapies to combat advanced melanoma and significantly decrease the mortality rate.12
Chemotherapy is analyzed within studies in combination or versus immunotherapy alone, but
there are many elements when patients and providers agree on a treatment plan.
Many patients rely solely on insurance or out-of-pocket expenses to cover the cost of
treatment. Immunotherapy and chemotherapy fall among different price points and this can be a
factor as to why patients delay, refuse, and or choose different therapy. Ipilimumab was the first
systemic agent to prolong survival in 2011 for advanced melanoma patients.13 Alternative
therapies such as target therapy and surgical interventions were less than $50,00, while
ipilimumab was more than $80,000 dollars.13 In subsequent years, as other immunotherapy drugs
were approved, there was a continued concern of cost. Between 2013 and 2015, the annualized
melanoma spending increased 21% leading to an increase of $61 million.13 The cost of
immunotherapy was $153 million in 2015.13 Although the immunotherapy drugs have offered
promise to patients, the prices are soaring.13 Patients may avoid costly immunotherapy by
scheduling early detection and prevention exams.
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A randomized clinical study published by Hamid et al in 2017, focused on the final
analysis of the survival of the therapy pembrolizumab versus chemotherapy in patients who have
acquired advanced melanoma.14 Patients eligible to participate in this study acquired advanced
melanoma and had been treated with two or more ipilimumab immunotherapy doses or MEK
inhibitors.14 This particular study had 180 patients randomized to pembrolizumab and 179
patients randomized to chemotherapy.14 After the follow-up of twenty-eight months, it was
unfortunate that a total of 368 patients died.14 The study also concluded that the survival rate with
pembrolizumab therapy was not more significant at either dose when compared to chemotherapy.
Although pembrolizumab did not indicate a significant difference compared to chemotherapy in
this specific study, Larkin et al concluded that immunotherapy options such as nivolumab
provide beneficial results to patients diagnosed with advanced melanoma.3
This randomized control study, published by Weber et al examines both safety and
adequacy of nivolumab, and compares it to chemotherapy as a second option treatment in
patients with advanced melanoma. Participating patients had to be at least eighteen-years-old
with metastatic melanoma that could not be treated with surgery. 15 In the study, patients were
randomly selected to receive an IV therapy of nivolumab containing 3mg per kg bi-weekly, or
chemotherapy every three weeks in combination with carboplatin.15 A total of 631 patients were
screened. There were zero fatalities among participants. The study showed that nivolumab had
the best responses as compared to chemotherapy with patients that had advanced melanoma.15
Larkin et al controlled, open-label phase III trial evaluated the survival of patients with
advanced melanoma who received chemotherapy versus nivolumab therapy. A total of 272
people were given nivolumab at random and a total of 133 were given chemotherapy at
random.16 The average survival rate for those on nivolumab with advanced melanoma was
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sixteen months as compared to fourteen months for patients on the chemotherapy regimen.16 The
results of this study made clear that nivolumab therapy had significantly better response rates as
compared to the chemotherapy. 16 However, this study indicated that there was no difference in
survival rate. Yet, the dropout rate of this study was significant: 233 patients on nivolumab were
discontinued from their treatment and 102 patients were discontinued from the chemotherapy
treatment.
Furthermore, a study published by Robert et al analyzes ipilimumab plus dacarbazine for
previously untreated metastatic melanoma patients. Five-hundred-two patients were assigned to
this study and received either ipilimumab plus dacarbazine or dacarbazine plus placebo given
over a span over several months. 17 Dacarbazine has never been shown to improve survival in any
randomized, controlled studies, but it is the drug that has been compared with new therapies,
such as immunotherapy. 17 Eligible patients were required to be at least eighteen-years-old with
untreated stage III or stage IV melanoma. If the patients received any treatments prior to
enrollment in this study, they were considered ineligible. Between August 2006 and January
2008, 250 patients were randomly assigned to the immunotherapy plus chemotherapy
combination and 252 patients were assigned to the chemotherapy plus placebo combination.17
There was a significant increase in disease progression in both groups, but more significant in the
chemotherapy plus placebo group.17 For the ipilimumab-dacarbazine group, survival was 11.2
months and 9.1 months for the dacarbazine group.17 The most common adverse effect was
elevated liver functions.17 This trial showed that there was much better improvement in overall
survival among patients with previously untreated metastatic melanoma that received the
ipilimumab therapy plus the dacarbazine compared to the dacarbazine alone.17
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Chemotherapy
Hamid et al is an open-label, randomized, phase III trial and it focuses on patients with
advanced NRAS-mutant melanoma. The study examines the efficacy of binimetinib versus
dacarbazine.18 This study looks at both the effectiveness and safety of both therapies. This study
was conducted in more than 100 hospitals globally and its patients had advanced NRAS-mutant
melanoma unable to be surgically resected. 18 The study concluded that binimetinib had a
positive survival by reducing progression compared to the other therapy, dacarbazine.18
Binimetinib, then, can be a possible promising treatment modality for patients with advanced
melanoma who did not have success or cannot afford other therapies.13
Ribas et al conducted a phase III randomized trial evaluated the survival rate, including
safety and effectiveness, in patients with advanced melanoma who received the tremelimumab
therapy. The study included 655 patients all randomly assigned. 19 The results concluded that the
overall survival rate for the therapy of tremelimumab was 12.6 months versus 10.7 months for
those on chemotherapy treatments. 19 Researchers concluded that there was no significant benefit
in terms of overall survival when comparing tremelimumab to chemotherapy because of various
similar results.19 Additional research is needed to find a more definitive conclusion.
Because chemotherapy has shown a negative effect for those suffering with advanced
melanoma focused on discovering the effects of other therapies such as paraoxonase-2, part of a
paraoxonase gene family proven to equip many antioxidant properties in parts of the body such
as the small intestine and central nervous system. 20 It also has properties of attacking oxidative
stress that is difficult on the body.20 The data shows that paraoxonase-2 could have beneficial
results in targeting those who have advanced melanoma.20 More investigation and further studies
would be needed to provide insight and efficacy of this therapy.
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Although therapies are beneficial they do come with side effects. People with advanced
melanoma usually have been treated with dacarbazine, a chemotherapy. Yet, dacarbazine has
many side effects, including phototoxic dermatitis.21 Treudler et al focuses on patients that have
received dacarbazine and have had this reaction, and examines a different chemotherapy agent
called temozolomide in hopes to eliminate the phototoxic dermatitis reaction. 21 This study
evaluated ten patients who were diagnosed with malignant melanoma. The patient population
aged between thirty-four and seventy-five years of age.21 Of the five patients that received the
temozolomide chemotherapy, not one encountered the phototoxic reaction. 21 Thus, not only does
temozolomide prevent phototoxic dermatitis reaction, it is a beneficial treatment for those
suffering from advanced melanoma. 21
Patients that have advanced melanoma use different types of therapies: immunotherapy,
chemotherapy, radiation, and surgical methods. Since 2011, immunotherapy has made a drastic
change in medicine especially with advanced melanoma patients. Chemotherapy was no longer
the first line treatment. 13 Overall, according to multiple studies, immunotherapy offers patients
the best outcome and survival rate compared to chemotherapy. The quality of life for patients
experiencing advanced melanoma that are on immunotherapy versus other treatments is better.
Although there are several different immunotherapy options and the patients are at risk for side
effects, the outcome is overall more beneficial for their health than chemotherapy is due to the
survival rate. In a study within this literature review, a patient had a combination therapy of
immunotherapy and radiation which both provided the patient with promising results even
though the patient developed colitis and the immunotherapy was therefore discontinued.11
Discussion/Analysis
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Based on the literature interpreted above, immunotherapy is a secure option for treating
advanced melanoma. The studies have showcased that there has been minimal benefit to
chemotherapy for the use of advanced melanoma in the last decade. Although there are
differences to each of the medications and the way they target the body of patients that suffer
advanced melanoma - patients that use immunotherapy have shown greater signs of survival
compared to immunotherapy.
Larkin et al established that there is a greater long-term survival at five years and the
quality of life by using nivolumab compared to other immunotherapy drugs.3 Since 2011,
immunotherapy has impacted patients diagnosed with advanced melanoma in numerous ways.
Chemotherapy used to be the gold standard and now it is not. 10 The incidence of melanoma is on
the rise and the gold standard that was chemotherapy is losing its place among treatment
protocols to immunotherapies and combination treatments. Chemotherapy still can play a role
within a specific group of patients that suffer from advanced melanoma, but it is not as common.
There are patients that do not qualify for any type of immunotherapy treatments and or have
undergone multiple treatments and were unsuccessful so now chemotherapy is the last option. It
does not have a significant and beneficial survival rate when compared to immunotherapy.
Although chemotherapy can be an option for patients that do not qualify for specific
treatments that suffer from advanced melanoma, the efficacy of the treatment is extremely low
when compared to immunotherapy. In addition to chemotherapy not having an overall high
survival rate it comes with a variety of side effects including , but not limited to hair loss,
vomiting, nausea, fatigue, and increased infection. The goal of the chemotherapy treatment is to
shrink the cancer, but it has been shown that several months later it typically returns and
sometimes even more aggressively.22
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Immunotherapy’s overall survival rate offers patients and their families much more time
of survival than chemotherapy. Indeed, there are adverse effects that can potentially affect a
patient's everyday life such as colitis, fatigue, nausea, and skin rash. Despite the list of side
effects and what the advanced melanoma patient may experience, there have been promising
results for the patient's overall survival. A study done by Larkin et al patients with advanced
melanoma had a greater long-term survival at five years and quality of life using immunotherapy
drugs, specially nivolumab or a combination of nivolumab and ipilimumab. 3 The use of
immunotherapy drugs has been on the rise over the last decade and has become the primary form
of treatment for patients with advanced melanoma. This study has been a primary example of
how immunotherapy has been beneficial for patients that have been diagnosed with advanced
melanoma.
Cancer cells typically avoid the immune system including melanoma cells. This allows
the immunotherapy drugs to offer patients better potential for survival. The immunotherapy
therapies help to increase the immune response and while doing this it increases the response of
the immune system in order for the cells to recognize and destroy melanoma cells.
As mentioned, the immunotherapy drugs do offer the best overall survival, but there is
still more research among the types of immunotherapy medications that need to be done. It
would be beneficial to compare individual and combination immunotherapies among the same
group of advanced melanoma patients. This would allow researchers, providers, and patients to
succeed at a longer overall survival rate now that the primary treatment has been shifted to
immunotherapy for advanced melanoma patients.
With this all means that patients are able to increase their life expectancy and with this be
able to enjoy life to its fullest and complete things and spend quality time with their loved ones
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while also surviving a terrible disease, advanced melanoma. The immunotherapy drugs will
additionally provide less abuse on the body compared to chemotherapy. As mentioned, there are
a list of side effects and at times the therapies have to be discontinued due to this. When
analyzing the different side effects immunotherapy still offers the body more tolerable side
effects compared to chemotherapy. There overall is less abuse on the body and the patient will be
able to continue with their everyday life even while they are undergoing treatment.
Overall, the most beneficial treatment for patients suffering from advanced melanoma is
immunotherapy. Multiple studies throughout this literature have analyzed immunotherapy,
chemotherapy, and both treatments in combination and the overall analysis is that
immunotherapy is the best treatment for patients that are suffering from advanced melanoma.

Conclusion
The goal of this literature review is to examine studies for patients diagnosed with
advanced melanoma and determine the lead therapies that provide better survival - specifically
comparing immunotherapy versus chemotherapy. The studies overall showed that the
immunotherapy treatment is a better alternative compared to the chemotherapy. The overall
decision of therapies for the patients are individualized and include a multitude of factors that
should be considered such as: efficacy, cost, and benefit towards the patients survival. Between
both therapy options there is a list of adverse reactions that should be considered and/or the
patient should be made aware of prior to beginning treatment. Immunotherapy is the most
considered therapy treatment against advanced melanoma.
The analyzed studies investigated the overall survival, safety, efficacy, and other
therapies that can benefit patients that suffer from advanced melanoma. Based on the literature,
immunotherapy provided patients a better outcome than chemotherapy did, making
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immunotherapy the gold standard for patients with advanced melanoma. Immunotherapy drugs
for advanced melanoma patients do have considerable side effects, but the overall survival
provides hope to patients and their families.
Luckily patients have been able to see a tremendous amount of results from the
immunotherapy drugs and are able to have a better survival. There is still an opportunity within
this topic to evaluate in more specific which immunotherapy types are most beneficial. Being
able to provide research can help providers and patients decide which immunotherapy drug
would be best fit to treat their advanced melanoma. All in all, the review of the literature shows
that immunotherapy is more beneficial and provides an overall better survival compared to
chemotherapy.
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